OncoTricks

Cancer clots and oral iron, Nov 4, 2026

A clot with cancer, in clinic: which anticoagulant for which tumor, and when apixaban can drop

If you remember one thingA tumor sitting in the gut or the urinary tract bleeds more on edoxaban and rivaroxaban; apixaban or low molecular weight heparin are the choices there. Apixaban is full dose for the first 6 months. The 2.5 mg twice-daily dose was tested only after that.

Concepts first

Cancer-associated clot
Deep vein thrombosis or pulmonary embolism (venous thromboembolism) in a patient with active cancer: under treatment, recently diagnosed, or metastatic.
Low molecular weight heparin
Enoxaparin or dalteparin, injected under the skin once or twice a day. No gut absorption, few drug interactions. Dalteparin was the comparison arm in the four treatment trials below.
Direct oral anticoagulant
A pill that blocks one clotting factor: apixaban, rivaroxaban, edoxaban (factor Xa), dabigatran (thrombin).
Luminal tumor
A cancer with a surface inside a hollow organ: esophagus, stomach, colon, rectum, bladder, an unresected primary. It can ooze into the lumen.
Major bleeding
Fatal, in a critical site (brain, spine, eye, pericardium), or dropping hemoglobin by 2 g/dL or needing 2 or more units of blood (the international definition used in these trials).
Clinically relevant bleeding
Major bleeding plus bleeding that is not major but still needs a visit, a test, a dose change or a procedure.
Treatment and extended phase
Treatment: the first 6 months after the clot. Extended: anything after that, while the cancer is still active.
Hazard ratio
The event rate on one drug or dose divided by the other; under 1 favors the first. A subhazard ratio is the same, counting death as a competing event.
Noninferior
Shown to be not worse than the comparator by more than a preset margin.

Three pills against the same injection

more major bleeding

Edoxaban, Hokusai VTE Cancer, 1,046 patients

6.9% vs 4.0%

Major bleeding at 12 months against dalteparin. Fewer recurrent clots: 7.9% vs 11.3%. The excess bleeding was confined to gastrointestinal cancers, mostly upper gut.

more bleeding in the gut

Rivaroxaban, SELECT-D, 406 patients

13% vs 4%

Clinically relevant non-major bleeding at 6 months, mostly gastrointestinal or urologic. Major bleeding 6% vs 4%. Fewer recurrent clots: 4% vs 11%.

no excess bleeding

Apixaban, Caravaggio, 1,155 patients

3.8% vs 4.0%

Major bleeding at 6 months. Recurrent clots 5.6% vs 7.9%. Gastrointestinal cancers: 9 major bleeds in each arm.

The recurrence bars for all four cancer trials are on Oct 9, "A true failure". Here, the bleeding.

The worst case: esophageal and gastroesophageal cancer on rivaroxaban.Major bleeding 36% vs 11% with dalteparin. After an interim safety review of the first 220 patients, SELECT-D stopped enrolling these cancers (Young 2018, summarized in Ay 2019). In Hokusai, edoxaban added 7.9 percentage points of major bleeding in gastrointestinal cancer, and 71% of those bleeds were in the upper gut (Mulder 2020; Kraaijpoel 2018).

ADAM VTE, the smaller apixaban trial, 287 patients.Major bleeding 0% with apixaban and 1.4% with dalteparin; recurrent clots 0.7% vs 6.3% (McBane 2020).

Why the gut tumor matters

A TUMOR IN THE LUMEN (A HYPOTHESIS)Pill drug in the lumenfriable surfaceBlood side: every anticoagulant reaches the tumorEdoxaban, rivaroxaban: more bleeding hereApixaban: no excess in Caravaggio

The mechanism is not proven.A high drug concentration in the gut lumen acting on the tumor or on chemotherapy-damaged mucosa is the explanation offered in the review literature (Ay 2019). The practical point stands without it: the excess bleeding sits where the tumor has a raw surface.

Pick the drug by the tumor

Luminal gut or urinary tumor in placeEsophagus, stomach, colon, rectum, bladder, unresected primary, or recent bleeding from the tumor.
Apixaban or low molecular weight heparin.
Avoid edoxaban and rivaroxaban.
Other tumors, resected primariesAny of the trial drugs is reasonable: apixaban, rivaroxaban, edoxaban, or low molecular weight heparin.
Apixaban was added to the American Society of Clinical Oncology guideline for treatment with a strong recommendation (Key 2023).
Low molecular weight heparin wins whenVomiting or cannot swallow; absorption in doubt; a strong interacting drug (next box); platelets low and changing day to day.
Interactions: what the trials excludedCaravaggio and SELECT-D excluded strong inhibitors and inducers of CYP3A4 and P-glycoprotein (the liver enzyme and gut pump that clear these pills). Rifampin, carbamazepine, phenytoin, azole antifungals, HIV protease inhibitors: no trial data, check with pharmacy.

Platelets: the lines are 50,000 and 25,000.International guidance, all with low molecular weight heparin (Samuelson Bannow 2018, summarized in Xirou 2025):
50,000 or more: full dose, no transfusion.
25,000 to 50,000, high-risk clot (symptomatic proximal leg clot, pulmonary embolism): full dose with platelet transfusion to keep 40,000 to 50,000.
25,000 to 50,000, lower-risk clot (distal leg, subsegmental, catheter): half dose or prophylactic dose.
Under 25,000: hold; restart full dose above 50,000.
The pill trials did not test low counts.

The trap: 2.5 mg too early

APIXABAN FOR A CANCER CLOT (NOT TO SCALE)10 mgx2 a day5 mg twice a daytreatment phase5 or 2.5 mgextended phaseDay 1Day 8Month 6Caravaggio, ADAM VTE: full doseAPI-CAT2.5 mg here:never tested2.5 mg here:tested, works

Why people drop it early.For atrial fibrillation only, the US label lowers apixaban to 2.5 mg twice daily when 2 of 3 are present: age 80 or older, weight 60 kg or less, creatinine 1.5 mg/dL or more (the rule used in ARISTOTLE, Granger 2011). That rule belongs to stroke prevention, not to a fresh clot. In the cancer treatment trials, everyone got 10 mg twice daily for 7 days, then 5 mg twice daily (Agnelli 2020; McBane 2020).

API-CAT: what 2.5 mg did after 6 months

1,766 patients with active cancer who had already completed at least 6 months of anticoagulation (median 8 months from the clot), randomized, double blind, to apixaban 2.5 or 5 mg twice daily for 12 months (Mahé 2025).

Who bleeds in the extended phase, whatever the dose.Anemia or low platelets (subhazard ratio 1.93), age 75 or older (1.51), a pulmonary embolism as the first event (1.47), male sex (1.38) (Mahé 2026, post hoc).

The same pattern without cancer.AMPLIFY-EXT, after 6 to 12 months of treatment: recurrence 1.7% with apixaban 2.5 mg and 1.7% with 5 mg, against 8.8% with placebo (Agnelli 2013).

Decide at the bedside

1. Platelets under 50,000, or bleeding now?
yes
Not a standard-dose dayBleeding: treat the bleed first. Platelets 25,000 to 50,000: low molecular weight heparin, full dose with transfusion for a high-risk clot, reduced dose for a lower-risk clot. Under 25,000: hold.
no
2. Tumor in the gut or urinary lumen, still in place?
yes
Apixaban or low molecular weight heparinNot edoxaban, not rivaroxaban.
no
3. Vomiting, poor absorption, or a strong CYP3A4 and P-glycoprotein drug?
yes
Low molecular weight heparin
no
4. Start a pillApixaban 10 mg twice daily for 7 days, then 5 mg twice daily. Or rivaroxaban, or edoxaban after 5 days of heparin.
month 6
Cancer still active? ContinueApixaban 2.5 mg twice daily is now an option (API-CAT). Recurrence or high clot risk: stay at 5 mg.

The tumor picks the drug. The calendar picks the dose.

Check yourself

Question 1Gastric cancer, primary in place, new pulmonary embolism, platelets 180,000. Edoxaban?

No. Luminal upper gut tumor: edoxaban added major bleeding in gastrointestinal cancer, mostly upper gut. Apixaban or low molecular weight heparin.

Question 2Lung cancer, leg clot 5 weeks ago, apixaban 5 mg twice daily. Age 81, 58 kg. Someone writes "reduce to 2.5 mg". Do you?

No. Age and weight are the atrial fibrillation rule. For a clot, 2.5 mg was tested only after at least 6 months of full-dose treatment.

Question 3Colon cancer resected 2 years ago, now liver metastases on chemotherapy, clot 8 months ago, no recurrence, no bleeding. What dose now?

Cancer is active, so continue. Apixaban 2.5 mg twice daily matched 5 mg for recurrence and caused less clinically relevant bleeding in API-CAT.

Sources

Retrieved from PubMed and the US prescribing information, read on Nov 5, 2026.

  1. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018. doi:10.1056/NEJMoa1711948
  2. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer study. Thromb Haemost 2018. doi:10.1055/s-0038-1667001
  3. Mulder FI, van Es N, Kraaijpoel N, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res 2020;185:13-19. doi:10.1016/j.thromres.2019.11.007
  4. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018. doi:10.1200/JCO.2018.78.8034
  5. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer (Caravaggio). N Engl J Med 2020. doi:10.1056/NEJMoa1915103
  6. Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021. doi:10.1055/s-0040-1720975
  7. McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020. doi:10.1111/jth.14662
  8. Mahé I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism (API-CAT). N Engl J Med 2025. doi:10.1056/NEJMoa2416112
  9. Mahé I, Chapelle C, Girard P, et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol 2026. doi:10.1016/S2352-3026(25)00291-1
  10. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism (AMPLIFY-EXT). N Engl J Med 2013. doi:10.1056/NEJMoa1207541
  11. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med 2011. doi:10.1056/NEJMoa1107039
  12. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019. doi:10.1093/annonc/mdz111
  13. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018. doi:10.1111/jth.14015
  14. Xirou V, Patell R. STARTing to bridge the evidence gap: management of cancer-associated thrombosis with concomitant thrombocytopenia. Res Pract Thromb Haemost 2025;9:103165. doi:10.1016/j.rpth.2025.103165
  15. Apixaban (Eliquis) US prescribing information, section 2.2, dose adjustment in atrial fibrillation.
  16. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023. doi:10.1200/JCO.23.00294